Baricitinib shows sustained long-term efficacy in pediatric atopic dermatitis
Baricitinib demonstrated sustained long-term efficacy in treating pediatric patients with moderate-to-severe atopic dermatitis, according to a study that assessed the long-term efficacy and safety of baricitinib in children who had previously responded to treatment after 16 weeks.
The extension study included 467 pediatric patients who received up to 750.7 patient-years of treatment. Responders and partial responders to baricitinib at Week 16 were randomized to continue receiving either placebo or baricitinib at doses of 1-mg, 2-mg, or 4-mg equivalents. Non-responders transitioned to open-label 4-mg baricitinib.
Overall, 56.8% of patients receiving the 4-mg dose achieved a validated Investigator Global Assessment-Atopic Dermatitis score of 0/1 at Week 52, outperforming other treatment groups.
The safety profile remained favorable, with most adverse events being mild to moderate in severity.
Reference
Wollenberg A, Ikeda M, Chu CY, et al. Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years. J Dermatolog Treat. 2024;35(1):2411834. doi: 10.1080/09546634.2024.2411834. Epub 2024 Nov 10. PMID: 39522957.
